Your browser does not fully support modern features. Please upgrade for a smoother experience.
Peptide Stability: History
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor: Yu Peng

Peptide stability is the ability of a peptide to retain its chemical integrity and relevant physical state under specified storage, formulation, or biological conditions [1][2]. Chemical changes can alter individual residues or cleave the backbone, whereas physical instability includes self-association into soluble aggregates, precipitates, or ordered fibrils. Sequence, concentration, pH, temperature, agitation, and contact with surfaces can influence these processes; stability therefore refers to a stated environment and observation period [2]. In biological fluids, resistance to proteolytic degradation contributes to persistence, but circulating exposure also reflects distribution and elimination [1][3]. Stability engineering may involve sequence modification, conformational restriction, formulation changes, or attachment of groups that promote albumin binding [1][4]. These interventions can change biological activity as well as degradation rates. An albumin-binding modification of a PCSK9 inhibitory peptide, for example, improved serum stability and activity in animals despite reducing measured binding potency. Assessment consequently distinguishes molecular integrity and aggregation from retained target binding and functional activity [1][2].

  • peptide stability
  • proteolysis
  • aggregation
  • formulation

Protein purification and stability • Molecular Biology • Biochemistry, Genetics and Molecular Biology • Life Sciences

References

  1. Yuhui Zhang; Li Wang; Benjamin J. Tombling; Carmen Lammi; Yen-Hua Huang; Yue Li; Martina Bartolomei; Bin Hong; David J. Craik; Conan K. Wang; Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide. J. Am. Chem. Soc. 2022, 144, 19485-19498. [CrossRef]
  2. Karolina L. Zapadka; Frederik J. Becher; A. L. Gomes dos Santos; Sophie E. Jackson; Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus 2017, 7, 20170030-20170030. [CrossRef]
  3. Daniel J. Drucker; Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 2019, 19, 277-289. [CrossRef]
  4. Markus Muttenthaler; Glenn F. King; David J. Adams; Paul F. Alewood; Trends in peptide drug discovery. Nat. Rev. Drug Discov. 2021, 20, 309-325. [CrossRef]
More
This entry is offline, you can click here to edit this entry!
Write an Entry